{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01308",
      "entity_text" : "insulin",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:O14842",
      "entity_text" : "GPR40",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Despite these unanswered questions, the evidence from both animal models and in initial human clinical trials suggests that GPR40 agonists effectively increase glucose dependent insulin secretion with minimal risk of hypoglycemia or evidence of beta-cell toxicity.",
  "reading_complete" : "2020-07-28T12:10:24Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T12:09:27Z",
  "trigger" : "increase",
  "evidence" : [ "GPR40 agonists effectively increase glucose-dependent insulin" ],
  "pmc_id" : "3920793",
  "score" : 0
}